Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1638 - Quality of Life (QoL) of patients (pts) with metastatic pancreatic cancer (mPAC) initiating first-line chemotherapy (CT) in routine practice


09 Sep 2017


Poster display session


Pancreatic Cancer


Berta Laquente


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


B. Laquente1, T. Macarulla2, C. Bugés3, M. Martín4, C. García5, E. Dotor6, S. Merino7, L. Visa8, T. Martín9, M. Pedraza10, R. Guardeño11, L. Pellín12, D. Vilanova12, A. García11

Author affiliations

  • 1 Medical Oncology, Institut Català d'Oncologia, 08908 - L'Hospitalet de Llobregat/ES
  • 2 Medical Oncology, Hospital Universitari Vall d’Hebron, Barcelona/ES
  • 3 Medical Oncology, Institut Català d'Oncologia (ICO) - Hospital Germans Trias i Pujol, Badalona/ES
  • 4 Medical Oncology, Hospital de Sant Pau, 08026 - Barcelona/ES
  • 5 Medical Oncology, Complejo Hospitalario de Burgos, 09006 - Burgos/ES
  • 6 Medical Oncology, Corporació Sanitaria Parc Taulí, 08208 - Sabadell/ES
  • 7 Medical Oncology, Hospital Sant Joan de Reus, 43204 - Reus/ES
  • 8 Medical Oncology, Hospital del Mar, 8003 - Barcelona/ES
  • 9 Medical Oncology, Hospital Universitario de Salamanca, 37007 - Salamanca/ES
  • 10 Medical Oncology, Complejo Asistencial Universitario de León, 24001 - León/ES
  • 11 Medical Oncology, Institut Català d’Oncologia (ICO), 17007 - Girona/ES
  • 12 Medical Affairs, Celgene S.L.U., Madrid/ES


Abstract 1638


Considering the physical decline of mPAC pts, the assessment of QoL becomes a matter of major concern. We aimed to assess the QoL of mPAC pts treated with first-line CT in routine practice.


Observational, prospective, multicenter study including mPAC pts who started first-line CT between 2014 and 2015 in 12 Spanish centers. Treatment and clinical characteristics were recorded at CT start (baseline [BL]). The patients’ QoL, ECOG, and Karnofsky index (KI) were measured at BL, at days 15 and 30, and every 4 weeks up to 6 mo of CT. QoL was measured using the EORTC QLQ-C30 global health status questionnaire (QLQ). Other variables included treatment response, overall survival (OS), and progression-free survival (PFS).


The study sample included 117 pts with a median age of 65 years (range 37-84). Metastases were mostly hepatic (75%). At BL, median weight loss (last 3 mo) was 9.2%, ECOG was 0-1 and 2 in 82% and 18% of pts, respectively, and KI was 70-80 and 90-100 in 48% and 52% of pts, respectively. Main first-line CT was gemcitabine in monotherapy (19%) or combined with nab-paclitaxel (65%). Overall, median OS and PFS were 9.0 mo (95% CI 6.4-10.6) and 6.0 mo (4.6-7.8), respectively; 3% and 28% of pts achieved a complete and partial response, respectively, with stable disease in 39% of pts. During the follow-up, 64% of pts improved their QoL; the KI showed no significant changes. Of 19 pts with BL ECOG 2, between 67% and 100% had improved their QLQ score at visits at the 1st mo and following. At BL, pts with KI 70-80 had poorer QoL, but experienced a greater improvement than those with KI 90-100 (p = 0.015), reaching similar QLQ scores after 2 mo of CT. A similar trend was observed in pts with ECOG 0-1 vs. 2 (p 


The EORTC QLQ-C30 questionnaire is suitable for measuring the QoL of mPAC pts undergoing CT. BL QLQ-C30 ≥50, KI 90-100, and weight loss ≤10% were associated with a greater OS. Most pts improved their QoL during CT, including those with poorer ECOG and KI at BL.

Clinical trial identification


Legal entity responsible for the study

Celgene, S.L.


Celgene, S.L.


M. Martín, A. García: Temporary consultant collaborator with Celgene. L. Pellín, D. Vilanova: Employee of Celgene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.